Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients

S. Y. Nam, K. R. Kim, B. S. Cha, Y. D. Song, S. K. Lim, H. C. Lee, K. B. Huh

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the effects of low-dose growth hormone (GH) therapy combined with diet restriction on changes in body composition and the consequent change in insulin resistance in newly-diagnosed obese type 2 diabetic patients. DESIGN: Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n = 9; rhGH, 0.15 IU/kg body weight/week) or placebo (n = 9) for 12 weeks. SUBJECTS: Eighteen newly-diagnosed obese type 2 diabetic patients (age 42-56y, body mass index 28.1 ± 2.7 kg/m2). MEASUREMENTS: Body composition and fat distribution parameters (by bioelectrical impedance analyzer and CT scans), serum IGF-1; serum glucose, insulin and free fatty acid (FFA) during oral glucose tolerance test (OGTT); HbA1c; serum lipid profiles; and glucose disposal rate (GDR) by euglycemic hyperinsulinemic clamp at baseline and after treatment. RESULTS: The fraction of body weight lost as fat lost was significantly greater (0.98 ± 0.39 vs 0.52 ± 0.32 kg/kg, P < 0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P < 0.05). Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group. GDR the was significantly increased in only the GH-treated group (4.67 ± 1.05 vs 6.95 ± 0.91 mg/kg/min, P < 0.05). The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat area/muscle area (r = 0.588, P = 0.001). Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA1c were significantly decreased after GH treatment. LDL-cholesterol level was decreased in only the GH-treated group. CONCLUSION: Low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.

Original languageEnglish
Pages (from-to)1101-1107
Number of pages7
JournalInternational Journal of Obesity
Volume25
Issue number8
DOIs
Publication statusPublished - 2001 Aug 18

Fingerprint

Intra-Abdominal Fat
Growth Hormone
Insulin Resistance
Diet
Muscles
Glucose
Placebos
Therapeutics
Glucose Tolerance Test
Body Composition
Serum
Nonesterified Fatty Acids
Body Weight
Insulin
Body Fat Distribution
Glucose Clamp Technique
Electric Impedance
Insulin-Like Growth Factor I
LDL Cholesterol
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

@article{78c2a98a8231417ab5af9bbd06690259,
title = "Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients",
abstract = "OBJECTIVE: To evaluate the effects of low-dose growth hormone (GH) therapy combined with diet restriction on changes in body composition and the consequent change in insulin resistance in newly-diagnosed obese type 2 diabetic patients. DESIGN: Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n = 9; rhGH, 0.15 IU/kg body weight/week) or placebo (n = 9) for 12 weeks. SUBJECTS: Eighteen newly-diagnosed obese type 2 diabetic patients (age 42-56y, body mass index 28.1 ± 2.7 kg/m2). MEASUREMENTS: Body composition and fat distribution parameters (by bioelectrical impedance analyzer and CT scans), serum IGF-1; serum glucose, insulin and free fatty acid (FFA) during oral glucose tolerance test (OGTT); HbA1c; serum lipid profiles; and glucose disposal rate (GDR) by euglycemic hyperinsulinemic clamp at baseline and after treatment. RESULTS: The fraction of body weight lost as fat lost was significantly greater (0.98 ± 0.39 vs 0.52 ± 0.32 kg/kg, P < 0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6{\%}, P < 0.05). Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group. GDR the was significantly increased in only the GH-treated group (4.67 ± 1.05 vs 6.95 ± 0.91 mg/kg/min, P < 0.05). The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat area/muscle area (r = 0.588, P = 0.001). Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA1c were significantly decreased after GH treatment. LDL-cholesterol level was decreased in only the GH-treated group. CONCLUSION: Low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.",
author = "Nam, {S. Y.} and Kim, {K. R.} and Cha, {B. S.} and Song, {Y. D.} and Lim, {S. K.} and Lee, {H. C.} and Huh, {K. B.}",
year = "2001",
month = "8",
day = "18",
doi = "10.1038/sj.ijo.0801636",
language = "English",
volume = "25",
pages = "1101--1107",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "8",

}

Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. / Nam, S. Y.; Kim, K. R.; Cha, B. S.; Song, Y. D.; Lim, S. K.; Lee, H. C.; Huh, K. B.

In: International Journal of Obesity, Vol. 25, No. 8, 18.08.2001, p. 1101-1107.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients

AU - Nam, S. Y.

AU - Kim, K. R.

AU - Cha, B. S.

AU - Song, Y. D.

AU - Lim, S. K.

AU - Lee, H. C.

AU - Huh, K. B.

PY - 2001/8/18

Y1 - 2001/8/18

N2 - OBJECTIVE: To evaluate the effects of low-dose growth hormone (GH) therapy combined with diet restriction on changes in body composition and the consequent change in insulin resistance in newly-diagnosed obese type 2 diabetic patients. DESIGN: Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n = 9; rhGH, 0.15 IU/kg body weight/week) or placebo (n = 9) for 12 weeks. SUBJECTS: Eighteen newly-diagnosed obese type 2 diabetic patients (age 42-56y, body mass index 28.1 ± 2.7 kg/m2). MEASUREMENTS: Body composition and fat distribution parameters (by bioelectrical impedance analyzer and CT scans), serum IGF-1; serum glucose, insulin and free fatty acid (FFA) during oral glucose tolerance test (OGTT); HbA1c; serum lipid profiles; and glucose disposal rate (GDR) by euglycemic hyperinsulinemic clamp at baseline and after treatment. RESULTS: The fraction of body weight lost as fat lost was significantly greater (0.98 ± 0.39 vs 0.52 ± 0.32 kg/kg, P < 0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P < 0.05). Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group. GDR the was significantly increased in only the GH-treated group (4.67 ± 1.05 vs 6.95 ± 0.91 mg/kg/min, P < 0.05). The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat area/muscle area (r = 0.588, P = 0.001). Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA1c were significantly decreased after GH treatment. LDL-cholesterol level was decreased in only the GH-treated group. CONCLUSION: Low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.

AB - OBJECTIVE: To evaluate the effects of low-dose growth hormone (GH) therapy combined with diet restriction on changes in body composition and the consequent change in insulin resistance in newly-diagnosed obese type 2 diabetic patients. DESIGN: Double-blind and placebo-controlled trial of 25-kcal/kg IBW diet daily with GH (n = 9; rhGH, 0.15 IU/kg body weight/week) or placebo (n = 9) for 12 weeks. SUBJECTS: Eighteen newly-diagnosed obese type 2 diabetic patients (age 42-56y, body mass index 28.1 ± 2.7 kg/m2). MEASUREMENTS: Body composition and fat distribution parameters (by bioelectrical impedance analyzer and CT scans), serum IGF-1; serum glucose, insulin and free fatty acid (FFA) during oral glucose tolerance test (OGTT); HbA1c; serum lipid profiles; and glucose disposal rate (GDR) by euglycemic hyperinsulinemic clamp at baseline and after treatment. RESULTS: The fraction of body weight lost as fat lost was significantly greater (0.98 ± 0.39 vs 0.52 ± 0.32 kg/kg, P < 0.05) and visceral fat area was decreased more in the GH-treated group compared to the placebo-treated group (27.9 vs 21.6%, P < 0.05). Lean body mass and muscle area were reduced in the placebo-treated group, whereas an increase in both was observed in the GH-treated group. GDR the was significantly increased in only the GH-treated group (4.67 ± 1.05 vs 6.95 ± 0.91 mg/kg/min, P < 0.05). The GH-induced increase in GDR was positively correlated with the decrease in the ratio of visceral fat area/muscle area (r = 0.588, P = 0.001). Serum glucose levels and insulin- and FFA-area under the curve during OGTT and HbA1c were significantly decreased after GH treatment. LDL-cholesterol level was decreased in only the GH-treated group. CONCLUSION: Low-dose GH treatment combined with dietary restriction resulted not only in a decrease of visceral fat but also in an increase of muscle mass with a consequent improvement of the insulin resistance observed in obese type 2 diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=0034901778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034901778&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0801636

DO - 10.1038/sj.ijo.0801636

M3 - Article

C2 - 11477493

AN - SCOPUS:0034901778

VL - 25

SP - 1101

EP - 1107

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 8

ER -